The Market for Pharmaceuticals in Brazil, Russia, India & China

The Market for Pharmaceuticals in Brazil, Russia, India & China

Evaluate the status, opportunities and threats for pharmaceutical companies in Brazil, Russia, India and China now and in the future. Market forecasts to 2014 are provided, plus free quarterly-updated market outlook reports on each country, keeping you up to date with developments for a full year.

These leading emerging economies represent a combined pharmaceutical market of US$127 billion. How have they emerged from the economic downturn? Where do commercial opportunities exist for pharmaceutical companies over the 2011-16 forecast period?

Putting things in perspective...

With strong economic growth, a combined population of 2.9 billion people and significant unmet healthcare needs, challenges and opportunities remain in BRIC pharmaceutical markets. Their combined market, including pharmacy and hospital sales, is valued at US$127.0 billion at retail prices. This market is collectively lower than that found in leading markets such as the USA and Japan, but impressive growth rates mean that pharmaceutical companies should have long-term interests in these markets. China, in fact, is expected to become the second leading worldwide pharmaceutical market by 2016.

Sizeable opportunities exist

There are wide regional health expenditure differences within the BRIC markets, far more than in developed countries where health systems provide a more uniform coverage level. These four countries have a relatively wealthy urban population with a far greater spending power than their respective national average. In the case of China and India, these urban populations have grown rapidly, and number hundreds of millions. The challenge for these countries is to extend this level of wealth to the rest of the population, so that better levels of healthcare become affordable. China, for instance, plans to create a solid platform for universal healthcare access for all by 2020.

A long haul...

Pharmaceutical market growth has increased since the economic downturn in 2009. Market change, however, is expected to be incremental. Short-term opportunities exist to meet the health demands of the burgeoning middle classes, whilst future prospects are bright, fuelled by strong economic performance. An impressive pharmaceutical market growth projected in BRIC markets is expected to erode some of the commercial differences with the established, but more sluggish, pharmaceutical markets in North America, Japan and Europe. Only Brazil is expected to have a low market CAGR in US dollar terms over the 2011-2016 period, due to a weaker local currency over the period.

HIGHLIGHTS FROM THE REGION...

BRAZIL

The Brazilian pharmaceutical market is the third largest in the Americas region, behind the USA and Canada; it ranks first in the Latin American region. Pharmaceutical demand will continue to increase as the country emerged from the economic downturn in 2009, therefore the market outlook is positive for the 2011-2016 period. Higher consumption of patented and bioequivalent medicines in Brazil will continue, replacing consumption of similar medicines. Generics sales in Brazil, which represented 17.2% of the pharmacy sector by value and 21.3% by volume in 2010, are expected to continue to grow at a higher rate than the overall pharmacy sector. Recent acquisitions of local generic companies by major foreign multinationals have changed the shape of the generic sector, with multinationals now accounting for about 40.0% of the sector.

RUSSIA

Russia accounts for just under a third of the total Central & Eastern European pharmaceutical market, due to its population of 142 million; however, in per capita terms, Russia is also one of the smallest markets, comparing to Romania. The Russian pharmaceutical market is predicted to expand at a relatively high CAGR in US dollar terms over the next few years and will continue to be driven by import growth; a heavy reliance on imports has resulted from the lack of locally-manufactured innovative pharmaceuticals. Over the last few years, import growth has been boosted by the federal drug supply system (DLO). Around 80% of DLO funds are spent on imported pharmaceuticals. The government is currently implementing the Pharma 2020 Strategy, which aims to encourage growth in the local pharmaceutical industry for the period up to 2020.

INDIA

TThe Indian pharmaceutical market is highly competitive and remains dominated by low priced, domestically-produced generics. Despite having the second largest population in the world and a growing middle class with high healthcare expectations, India accounts for less than 2% of the world pharmaceutical market in value terms. In one of the world's better performing economies, spending on pharmaceuticals accounts for less than 1% of GDP and average per capita spending remains one of the lowest levels in the region. The Indian pharmaceutical industry is responsible for around 8% of world pharmaceutical production. Over the last couple of years, Indian pharmaceutical companies have been increasingly targeted by multinationals for both collaborative agreements and acquisitions. The biopharmaceutical sector in India is currently experiencing double digit growth and this is expected to continue, driven by the vaccines market.

CHINA

The MoH has made lower drug prices a top priority for health authorities in 2011. In January 2011, the MoH announced that the Essential Drugs List will be further expanded to cover nearly all government-sponsored grass-roots health institutions. The MoH will also focus on streamlining the centralised procurement and distribution of essential drugs, to bring down drug prices at the supply end and thus lower drug prices for patients. In December 2010, National Development and Reform Commission (NDRC) deputy director Zhu Zhixin reported that preliminary statistics showed the prices of basic medicines had dropped by nearly a third, since the implementation of the Essential Drugs List in August 2009. In November 2010, it was reported that the NDRC was planning to reduce the price of original research drugs, which are mostly manufactured by foreign

companies and are normally eligible for independent pricing.

More Information...

4 Markets Covered

EXECUTIVE SUMMARY

Including Espicom's at a glance strategic analysis and key data projections

MACROENVIRONMENT

Political, economic, legal and demographic analysis

EPIDEMIOLOGY

Disease burden and prevalence

HEALTHCARE

Organisation, expenditure, infrastructure, services and workforce

REGULATORY AFFAIRS

Regulatory developments and marketing registration/authorisation

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET ANALYSIS

Projections, product development, manufacturing and trade

COMPETITION

Trade associations, trade fairs, company intelligence and competitive strategies

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

OPPORTUNITIES & CHALLENGES

Espicom's unique strategic analysis

DIRECTORY

HEALTHCARE DATA - updated annually

A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.

Contents

• 4 Markets Covered
      Brazil
      Russia
      India
      China
• (SAMPLE REPORT TOC: CHINA)
• EXECUTIVE SUMMARY
  • Snapshot: Strategic Espicom Analysis
  • Snapshot: Key Data Projections
• MACROENVIRONMENT
• POLITICAL
• ECONOMIC
  • Projections
  • Government's Revaluation of CNY
• LEGAL
  • Administrative Protection
  • China Remains on USTR Priority Watch List
• DEMOGRAPHIC
  • Projections
  • Current Figures
  • Demographic Indicators
  • Births
  • Deaths
  • Infant Deaths
  • Life Expectancy at Birth
• EPIDEMIOLOGY
• DISEASE BURDEN
  • Leading Causes of Mortality
• DISEASE PREVALENCE
  • Communicable Diseases
  • HIV/AIDS
• HEALTHCARE - ACCOMPANYING HEALTH STATISTICS
• ORGANISATION
  • Healthcare Reform Plan
  • Ministry of Health
  • Hospitals
  • Rural Healthcare
  • Red Cross Society of China
• EXPENDITURE
  • Projections
  • Latest Figures
  • Health Insurance
  • Public Health Insurance
  • Private Health Insurance
• INFRASTRUCTURE
  • Hospital Infrastructure
  • Outpatient Infrastructure
• SERVICES
  • Inpatient Analysis
  • Outpatient Analysis
• WORKFORCE
  • Projections
  • Current State
• REGULATORY AFFAIRS
• NATIONAL AUTHORITY
  • Department of Drug Registration
• REGULATORY DEVELOPMENTS
  • Revised GMP Regulations
• MARKETING REGISTRATION
  • Department of Drug Safety & Inspection
  • Department of Drug Market Compliance
  • Drug Classification
  • Regulatory Legislation
  • 2001 DAL Amendments
  • The Drug Import Regulation
  • GMP Regulations
  • Drug Approval Process
  • Clinical Trials
  • Quality Tests
  • Certification
  • POST-MARKETING SURVEILLANCE
  • Revoked Licences
  • Bribery Cases
• PROMOTION
  • Advertising
• PACKAGING
• PRICING & REIMBURSEMENT
• PRICING
  • National Pricing
• REIMBURSEMENT
  • China's National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory
• DISTRIBUTION CHANNELS
• DRUG WHOLESALING
  • Leading Wholesalers
  • Selected Wholesalers
  • Chindex
  • First China Pharmaceutical Group
  • Hainan Kangtong Pharmaceutical
  • Huazhong Pharmaceutical
  • Hunan Provincial Medicines & Health Products Import & Export Corp
  • Jointown Pharmaceutical Group
  • Nanjing Medical Company (NMC)
  • Shandong Medicines & Health Products Import & Export Corp
  • Shanghai Pharmaceutical
  • Sincer Pharmchem
  • Sinochem Jiangsu Suzhou Import Export Corp
  • Sinopharm
  • Tianjin Medicines & Health Products Import & Export Corp
  • Yong Yu
• DRUG RETAILING
  • Selected Pharmacy Chains
  • China BCT Pharmacy Group
  • ShenZhen Nepstar
• MARKET ANALYSIS
• SIZE
  • Projections
  • Historical Figures
• PRODUCT DEVELOPMENT
  • Mega New Drug Development Programme
  • Beijing Economic-Technological Development Area
  • Zhangjiang Hi-Tech Park
• MANUFACTURING
  • 11th Five Year Plan Targets
  • China to Turn Five Companies into International Producers
  • TRADE
  • Exports
  • Imports
  • Balance of Trade
• COMPETITION
• TRADE ASSOCIATIONS
  • CAPC
• CCCMHPIE
  • CPIA
  • RDPAC
  • RDPAC Members,
• TRADE FAIRS
  • Interphex China
  • PharmChina
• COMPANY INTELLIGENCE
  • Domestic Manufacturers
  • Aida Pharmaceuticals
  • Beijing Four Ring Biopharmaceutical
  • Beijing Union Pharmaceutical Factory
  • Changzhou Siyao Pharmaceuticals
  • China Pharmaceutical Group
  • CSPC Weisheng Pharmaceutical Company
  • C&O Pharmaceutical Technology
  • Fuzhou Antibiotic Group Corp
  • Haizhou Pharmaceutical
  • Heshuo Ephedrine Factory
  • Huazhong Pharmaceutical
  • Jiangsu Jiangan Pharmaceutical
  • Lansen Pharmaceutical
  • Ningbo Jierfu Pharmaceutical
  • North China Pharmaceutical Huasheng
  • Shanghai Fosun Pharmaceutical Company
  • Shanghai Pharmaceutical Group
  • Shenzhen Taitai Pharmaceutical Company
  • Shenzhen Zhijun Pharmaceutical Company
  • Shenzhen Salubris Pharmaceuticals
  • Sihuan Pharmaceutical Group
  • Sinobiopharma
  • Sinochem Group
  • Sinopharm
  • Simcere
  • Wenzhou Pharmaceutical Factory
  • Xiamen No.2 Pharmaceutical Factory
  • Xinhua Pharma
  • YiYuan Pharmaceutical
  • Zhejiang Hisun
  • Zhejiang Jingxin
  • Zhejiang Jinhua Lixin Fine Chemicals
  • Zhejiang Medicine Company
  • Multinational Manufacturers
  • Abbott
  • Allergan
  • Antibioticos
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Bayer
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Dragon Pharmaceuticals
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Hovione
  • Johnson & Johnson
  • Merck Sharp & Dohme
  • Mitsubishi Tanabe Pharma
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Rexim SA (Degussa)
  • Roche
  • sanofi-aventis
  • Servier
  • Takeda
• TRADITIONAL CHINESE MEDICINES
  • China Conducts Research on Toxicity and Side Effects of TCM
• COMPETITION
  • Company Intelligence
  • China Shineway Pharmaceutical Group
  • Guilin Sanjin Pharmaceutical Company
  • Tongjitang Chinese Medicines Company
• OTC PHARMACEUTICALS
• REGULATION
• MARKET SIZE
• COMPETITION
  • Company Intelligence
  • China Sky One Medical
  • Harbin Pharmaceutical Group
  • sanofi-aventis
• GENERIC PHARMACEUTICALS
• REGULATION
  • Prescribing Regulation
• MARKET SIZE
• COMPETITION
  • Company Intelligence
  • China Pharma Holdings
  • Desano
  • Mylan
  • Ranbaxy
  • Watson
• BIOLOGICS & BIOSIMILARS
• REGULATION
• MARKET SIZE
• COMPETITION
  • Company Intelligence
  • 3SBIO
  • Agenix
  • Anhui Anke Biotech
  • AutekBio
  • China Biologic Products
  • GeneScience
  • Genzyme
  • GlaxoSmithKline
  • Guangdong Techpool Bio-Pharma
  • Harbin Gloria Pharmaceuticals
  • Kun Run Biotechnology
  • Livzon Pharmaceutical
  • Merck Serono
  • Microbix
  • NeoStem
  • Novartis
  • Nuokang Bio-Pharmaceutical
  • OriGene
  • sanofi-aventis
  • Shenzhen Hepalink
  • Shenzhen Kexing Biotech
  • Simcere
  • Sinopharm
  • Sinovac Biotech
  • WuXi AppTec
  • Wuyi JiuYuan
  • Zhejiang Tianyuan Bio-Pharmaceutical Company
  • Zhuhai United Laboratories
• CONCLUSIONS: OPPORTUNITIES & CHALLENGES
  • Strategic Espicom Analysis
• MACROENVIRONMENT
• EPIDEMIOLOGY
• HEALTHCARE
• REGULATORY AFFAIRS
• PRICING & REIMBURSEMENT
• DISTRIBUTION CHANNELS
• MARKET
• COMPETITION
• OTC PHARMACEUTICALS
• GENERIC PHARMACEUTICALS
• BIOLOGICS & BIOSIMILARS
  • Radar Analysis
  • SWOT Analysis
• DIRECTORY
• GOVERNMENT ORGANISATIONS
• PHARMACEUTICAL COMPANIES
  • Foreign Pharmaceutical Companies
  • Local Pharmaceutical Companies
• TRADE ORGANISATIONS
• List of Tables
  • Espicom Analysis of the Pharmaceutical Market,
  • Key Data Projections,
  • Political Landscape,
  • Regional Ranking of Projected Economies,
  • Projected Economy,
  • Regional Ranking of Projected Demographics,
  • Projected Demographics,
  • Demographic Indicators,
  • Leading Causes of Death,
  • Reported Infectious Diseases, 2001-2008 (Rate/100,000 Population)
  • Regional Ranking of Projected Health Expenditure,
  • Projected Health Expenditure,
  • Healthcare Expenditure by Type, 1999-2007 (CNY Billions)
  • NCMS Funding and Expenditure,
  • Hospitals,
  • Hospitals by Region & Municipality,
  • Outpatient Institutions by Type,
  • Health Centres & Clinics by Region & Municipality,
  • Inpatient Admissions, 2002-2008 (Millions)
  • Inpatient Admissions by Type & Institution, 2008 (10,000s)
  • Outpatient Visits, 1999-2008 (Millions)
  • Outpatient Visits by Type & Institution, 2008 (Millions)
  • Regional Ranking of Projected Physicians,
  • Projected Number of Physicians,
  • Medical Personnel by Type, 2008 (000s)
  • Physicians by Region & Municipality, 2008 (000s)
  • ShenZhen Nepstar Drugstores by City,
  • Regional Ranking of Projected Pharmaceutical Markets,
  • Projected Pharmaceutical Market at Retail Prices,
  • Historical Pharmaceutical Market at Retail Prices,
  • TCM Industrial Output Value, 2000-2007 (CNY Billions)
  • Pharmaceutical Exports by Category, 2005-2009 (US$000s)
  • Pharmaceutical Exports by Country/Region, 2009 (US$000s)
  • Pharmaceutical Imports by Category, 2005-2009 (US$000s)
  • Imports of Raw Materials by Country/Region, 2009 (US$000s)
  • Imports of Antisera & Vaccines by Country/Region, 2009 (US$000s)
  • Imports of Medicaments by Country/Region, 2009 (US$000s)
  • Pharmaceutical Balance of Trade, 2005-2009 (US$000s)
  • Dragon Pharmaceuticals Revenues by Segment, 2009 (US$000s)
  • Espicom Analysis of the Pharmaceutical Market,
  • SWOT Analysis of the Pharmaceutical Market,
• List of Charts
  • Regional Comparison of Top 5 Projected Pharmaceutical Markets at Retail Prices,
  • Regional Comparison of Projected Pharmaceutical Market Share,
  • Historical Pharmaceutical Market at Retail Prices,
  • China's Pharmaceutical/Medical Device Industry Output, 1998-2007 (CNY Billions)
  • Pharmaceutical Exports, 2003-2009 (US$ Billions)
  • Pharmaceutical Imports, 2003-2009 (US$ Billions)
  • Pharmaceutical Imports by Country/Region, 2009 (%)
  • Pharmaceutical Balance of Trade, 2003-2009 (US$ Billions)
  • Radar Graph of the Pharmaceutical Market,

Related products